Status:
NOT_YET_RECRUITING
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
Lead Sponsor:
Fayoum University
Conditions:
Erythropoietin Resistant Anemia (EPO Resistant Anemia)
Eligibility:
All Genders
18+ years
Brief Summary
The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).
Detailed Description
Chronic kidney disease (CKD) is a common condition that has significant implications for patients' health and healthcare budgets. CKD is a major contributor to morbidity and mortality across the globe...
Eligibility Criteria
Inclusion
- Patients (and replacements) will be randomly selected by a raffle.
- All participants should be 18 years of age or older and agree to participate in the study after due clarification.
- Patients with end stage kidney disease (ESKD) on regular hemodialysis for more than 3 months.
Exclusion
- \- Patients with neoplasm, severe cardiovascular, cerebrovascular and liver diseases.
- Females with polycystic ovarian syndrome, those on hormonal replacement therapy and pregnant women.
- Patients with infection or autoimmune diseases.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT06983756
Start Date
June 1 2025
End Date
January 1 2026
Last Update
May 21 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.